Female Partners of Men With Erectile Dysfunction Receiving Vardenafil Have Improved Sexual Function: Results From a Randomized Double-Blind Placebo-Controlled Trial.Female Partners of Men With Erectile Dysfunction Receiving Vardenafil Have Improved Sexual Function: Results From a Randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. Double-Blind Placebo-Controlled Trial, William Fisher, University of Western Ontario Western is one of Canada's leading universities, ranked #1 in the Globe and Mail University Report Card 2005 for overall quality of education.[2] It ranked #3 among medical-doctoral level universities according to Maclean's Magazine 2005 University Rankings. ; Raymond C. Rosen, Robert Wood Johnson Medical School Robert Wood Johnson Medical School (often abbreviated RWJMS) is one of eight schools that comprise the University of Medicine and Dentistry of New Jersey (UMDNJ). RWJMS operates three campuses in New Jersey, in Piscataway, New Brunswick and Camden. ; Martin Mollen, Arizona Research Center; Gerald Brock, St. Joseph's Medical Center, Canada; Gary Karlin, Lawrenceville Urology Practice; Peter Pommerville, Can-med Clinical Research Inc.; Irwin Goldstein, Boston University School of Medicine Boston University School of Medicine (BUSM) is one of the graduate schools of Boston University. It is an American medical school located in the South End neighborhood of Boston, Massachusetts. ; Keith Bangerter, Bayer Healthcare Pharmaceuticals We compared Female Sexual Function Index (FSFI FSFI Female Sexual Function Index FSFI Federazione fra le Società Filateliche Italiane (Italian: Federation of the Italian Philatelic Societies) ) scores of female partners of men with ED receiving vardenafil or placebo to investigate improvements in multidimensions of female sexual function. This was a randomized, double-blind, multicenter, flexible-dose, parallel-group trial. Men over 18 years of age with ED for at least 6 months were randomized to receive vardenafil or placebo. Female partners had a screening FSFI score of at least 26.55 and were motivated to support their partners' treatment. A 4-week screening period was followed by 12 weeks of treatment. Vardenafil was initiated at 10 mg for the first 4 weeks; at 4 and 8 weeks, the dose could be maintained or titrated ti·trate tr. & intr.v. ti·trat·ed, ti·trat·ing, ti·trates To determine the concentration of (a solution) by titration or perform the operation of titration. to 5 mg or 20 mg. Changes in patients' overall response rates to the Sexual Encounter Profile question 3 (SEP 1. SEP - Someone Else's Problem. 2. (tool) SEP - A SASD tool from IDE. 3; Did your erection last long enough for you to have sexual intercourse?) and female partners' responses to the Quality of Life domain of the modified Sexual Life Quality Questionnaire (mSLQQ-QOL) at last observation carried forward (LOCF) were the primary efficacy measures. Changes in female partner's FSFI scores were monitored at LOCF. Vardenafil significantly improved SEP3 success rate and partner mSLQQ-QOL score compared with placebo. Total FSFI scores were significantly superior in the vardenafil group compared with placebo. Scores for all FSFI domains were also significantly higher in the vardenafil group compared with placebo, with the exception of the pain domain, where no significant changes occurred. Vardenafil was generally well-tolerated in male patients. Overall, treating male ED patients with vardenafil was associated with improvement in multidimensions of their female partners' sexual function, as assessed by the validated FSFI instrument. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion